{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:12:36Z","timestamp":1790856756909,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Our previous work has demonstrated that human follicular lymphoma (FL) infiltrating T cells are anergic, in part due to suppression by regulatory T cells. In this study, we identify pericellular adenosine, interacting with T cell-associated G protein-coupled A2A\/B adenosine receptors (AR), as contributing to FL T cell hyporesponsiveness. In a subset of FL patient samples, treatment of lymph node mononuclear cells (LNMC) with specific A2A\/B AR antagonists results in an increase in IFN-\u03b3 or IL-2 secretion upon anti-CD3\/CD28 Ab stimulation, as compared with that seen without inhibitors. In contrast, treatment with an A1 AR antagonist had no effect on cytokine secretion. As the rate limiting step for adenosine generation from pericellular ATP is the ecto-ATPase CD39, we next show that inhibition of CD39 activity using the inhibitor ARL 67156 partially overcomes T cell hyporesponsiveness in a subset of patient samples. Phenotypic characterization of LNMC demonstrates populations of CD39-expressing CD4+ and CD8+ T cells, which are overrepresented in FL as compared with that seen in normal or reactive nodes, or normal peripheral blood. Thirty percent of the FL CD4+CD39+ T cells coexpress CD25high and FOXP3 (consistent with regulatory T cells). Finally, FL or normal LNMC hydrolyze ATP in vitro, in a dose- and time-dependent fashion, with the rate of ATP consumption being associated with the degree of CD39+ T cell infiltration. Together, these results support the finding that the ATP-ectonucleotidase-adenosine system mediates T cell anergy in a human tumor. In addition, these studies suggest that the A2A\/B AR as well as CD39 are novel pharmacological targets for augmenting cancer immunotherapy.<\/jats:p>","DOI":"10.4049\/jimmunol.0900475","type":"journal-article","created":{"date-parts":[[2009,10,29]],"date-time":"2009-10-29T02:05:45Z","timestamp":1256781945000},"page":"6157-6166","source":"Crossref","is-referenced-by-count":81,"title":["Human Follicular Lymphoma CD39+-Infiltrating T Cells Contribute to Adenosine-Mediated T Cell Hyporesponsiveness"],"prefix":"10.1093","volume":"183","author":[{"given":"Shannon P","family":"Hilchey","sequence":"first","affiliation":[{"name":"James P. Wilmot Cancer Center, Lymphoma Biology Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J","family":"Kobie","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew R","family":"Cochran","sequence":"additional","affiliation":[{"name":"David H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, and Department of Microbiology and Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Secor-Socha","sequence":"additional","affiliation":[{"name":"David H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, and Department of Microbiology and Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyh-Chiang E","family":"Wang","sequence":"additional","affiliation":[{"name":"David H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, and Department of Microbiology and Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ollivier","family":"Hyrien","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, University of Rochester Medical Center , Rochester, NY 14642"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Richard","family":"Burack","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Center, Lymphoma Biology Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim R","family":"Mosmann","sequence":"additional","affiliation":[{"name":"David H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, and Department of Microbiology and Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally A","family":"Quataert","sequence":"additional","affiliation":[{"name":"David H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, and Department of Microbiology and Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H","family":"Bernstein","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Center, Lymphoma Biology Program"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,11,15]]},"reference":[{"key":"2025032603205253400_R1","first-page":"267","article-title":"Immunosuppressive strategies that are mediated by tumor cells.","volume-title":"Annu. Rev. Immunol.","year":"2007"},{"key":"2025032603205253400_R2","first-page":"263","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance.","volume-title":"Nat. Rev. Cancer","year":"2005"},{"key":"2025032603205253400_R3","first-page":"909","article-title":"Cancer immunotherapy: moving beyond current vaccines.","volume-title":"Nat. Med.","year":"2004"},{"key":"2025032603205253400_R4","first-page":"2765","article-title":"Cutting edge: critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis.","volume-title":"J. Immunol.","year":"2006"},{"key":"2025032603205253400_R5","first-page":"4240","article-title":"Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition.","volume-title":"J. Immunol.","year":"2007"},{"key":"2025032603205253400_R6","first-page":"1073","article-title":"A2A adenosine receptor induction inhibits IFN-\u03b3 production in murine CD4+ T cells.","volume-title":"J. Immunol.","year":"2005"},{"key":"2025032603205253400_R7","first-page":"3491","article-title":"Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function.","volume-title":"FASEB J.","year":"2008"},{"key":"2025032603205253400_R8","first-page":"4707","article-title":"Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo.","volume-title":"Blood","year":"2005"},{"key":"2025032603205253400_R9","first-page":"13132","article-title":"A2A adenosine receptor protects tumors from antitumor T cells.","volume-title":"Proc. Natl. Acad. Sci. USA","year":"2006"},{"key":"2025032603205253400_R10","first-page":"S457","article-title":"Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells.","volume-title":"Br. J. Pharmacol.","year":"2008"},{"key":"2025032603205253400_R11","first-page":"854","article-title":"Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours.","volume-title":"Int. J. Cancer","year":"1994"},{"key":"2025032603205253400_R12","first-page":"31","article-title":"A glance at adenosine receptors: novel target for antitumor therapy.","volume-title":"Pharmacol. Ther.","year":"2003"},{"key":"2025032603205253400_R13","first-page":"217","article-title":"Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation.","volume-title":"Semin. Thromb. Hemost.","year":"2005"},{"key":"2025032603205253400_R14","first-page":"95","article-title":"Ecto-enzyme and signaling functions of lymphocyte CD73.","volume-title":"Immunol. Rev.","year":"1998"},{"key":"2025032603205253400_R15","first-page":"5947","article-title":"Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia.","volume-title":"Clin. Cancer Res.","year":"2008"},{"key":"2025032603205253400_R16","first-page":"358","article-title":"Adenosine 5\u2032-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation.","volume-title":"Pharmacol. Ther.","year":"2006"},{"key":"2025032603205253400_R17","first-page":"339","article-title":"Alerting and tuning the immune response by extracellular nucleotides.","volume-title":"J. Leukocyte Biol.","year":"2003"},{"key":"2025032603205253400_R18","first-page":"613","article-title":"ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling.","volume-title":"Blood","year":"2003"},{"key":"2025032603205253400_R19","first-page":"3075","article-title":"High sensitivity of CD4+CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors.","volume-title":"J. Immunol.","year":"2005"},{"key":"2025032603205253400_R20","first-page":"6780","article-title":"T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5\u2032-adenosine monophosphate to adenosine.","volume-title":"J. Immunol.","year":"2006"},{"key":"2025032603205253400_R21","first-page":"1257","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.","volume-title":"J. Exp. Med.","year":"2007"},{"key":"2025032603205253400_R22","first-page":"4051","article-title":"Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3\/CD28-costimulated autologous and allogeneic CD8+CD25\u2212 and CD4+CD25\u2212 T cells.","volume-title":"J. Immunol.","year":"2007"},{"key":"2025032603205253400_R23","first-page":"4682","article-title":"K-Sample tests based on the likelihood ratio.","volume-title":"Comput. Stat.","year":"2007"},{"key":"2025032603205253400_R24","volume-title":"Nonparametric Statistical Methods","year":"1999"},{"key":"2025032603205253400_R25","first-page":"345","article-title":"Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.","volume-title":"Int. Immunol.","year":"2007"},{"key":"2025032603205253400_R26","first-page":"235","article-title":"Strategies for immunotherapy of cancer.","volume-title":"Adv. Immunol.","year":"2000"},{"key":"2025032603205253400_R27","first-page":"807","article-title":"Does the immune system see tumors as foreign or self?.","volume-title":"Annu. Rev. Immunol.","year":"2003"},{"key":"2025032603205253400_R28","first-page":"630","article-title":"Cancer vaccines: between the idea and the reality.","volume-title":"Nat. Rev. Immunol.","year":"2003"},{"key":"2025032603205253400_R29","first-page":"1352","article-title":"Cellular and humoral immunity to different types of human neoplasms.","volume-title":"Nature","year":"1968"},{"key":"2025032603205253400_R30","first-page":"265","article-title":"Eradication of established tumors by CD8+ T cell adoptive immunotherapy.","volume-title":"Immunity","year":"2000"},{"key":"2025032603205253400_R31","first-page":"181","article-title":"Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.","volume-title":"Adv. Immunol.","year":"2000"},{"key":"2025032603205253400_R32","first-page":"462","article-title":"Progress in the development of immunotherapy for the treatment of patients with cancer.","volume-title":"J. Intern. Med.","year":"2001"},{"key":"2025032603205253400_R33","first-page":"243","article-title":"Improving T cell therapy for cancer.","volume-title":"Annu. Rev. Immunol.","year":"2007"},{"key":"2025032603205253400_R34","first-page":"197","article-title":"Immunotherapy: bewitched, bothered, and bewildered no more.","volume-title":"Science","year":"2004"},{"key":"2025032603205253400_R35","first-page":"614","article-title":"Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells: flow cytometry studies with anti-A2A receptor monoclonal antibodies.","volume-title":"Mol. Pharmacol.","year":"1999"},{"key":"2025032603205253400_R36","first-page":"1600","article-title":"Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion.","volume-title":"Blood","year":"1997"},{"key":"2025032603205253400_R37","first-page":"25881","article-title":"Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells.","volume-title":"J. Biol. Chem.","year":"1997"},{"key":"2025032603205253400_R38","first-page":"5571","article-title":"HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak.","volume-title":"Blood","year":"2008"},{"key":"2025032603205253400_R39","first-page":"2602","article-title":"The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine.","volume-title":"Cancer Res.","year":"1997"},{"key":"2025032603205253400_R40","first-page":"8067","article-title":"ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1\u03b2 and IL-18 secretion in an autocrine way.","volume-title":"Proc. Natl. Acad. Sci. USA","year":"2008"},{"key":"2025032603205253400_R41","first-page":"8267","article-title":"Extracellular ATP in T-lymphocyte activation: possible role in effector functions.","volume-title":"Proc. Natl. Acad. Sci. USA","year":"1990"},{"key":"2025032603205253400_R42","first-page":"224","article-title":"Central role of Sp1-regulated CD39 in hypoxia\/ischemia protection.","volume-title":"Blood","year":"2009"},{"key":"2025032603205253400_R43","first-page":"808","article-title":"ATP drives lamina propria TH17 cell differentiation.","volume-title":"Nature","year":"2008"},{"key":"2025032603205253400_R44","first-page":"309","article-title":"CD39\/NTPDase-1 activity and expression in normal leukocytes.","volume-title":"Thromb. Res.","year":"2007"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/183\/10\/6157\/62696273\/9957.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/183\/10\/6157\/62696273\/9957.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T09:21:48Z","timestamp":1743240108000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/183\/10\/6157\/8053053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,11,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.0900475","relation":{},"ISSN":["1550-6606","0022-1767"],"issn-type":[{"value":"1550-6606","type":"electronic"},{"value":"0022-1767","type":"print"}],"subject":[],"published-other":{"date-parts":[[2009,11]]},"published":{"date-parts":[[2009,11]]}}}